Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    No Functional, Cognitive Benefits Achieved With PROFESS Regimens in Stroke Patients: Presented at ESC - (DGDispatch)
    ONTARGET Substudy Shows No Benefits for Combination Therapy for Prevention of Vascular Events in High-Risk Patients: Presented at ASH(HYP) - (DGDispatch)
    Effects of Methylphenidate Patch on Growth Minimal in Children With Attention Deficit Hyperactivity Disorder: Presented at APA - (DGDispatch)
    CDC Recommends Vaccine for Shingles - (DGNews)
    Antipsychotics Found to Have Different Ethnic and Metabolic Profiles: Presented at APA - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Recent Advancements in HIV / AIDS Treatment
      New Drug Update of 2007
      Pharmacotherapeutic Treatments for Hypertension Complicated with Proteinuria
      Battling Chronic Fatigue Syndrome
      A Parkinson's Disease Primer

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Treatment with Pioglitazone Induced Significant, Reversible Mitral Regurgitation
        Cholestatic Hepatitis as a Possible New Side-Effect of Oxycodone: A Case Report
        Atopic Dermatitis, Cutaneous Steroids and Cataracts in Children: Two Case Reports
        Successful Treatment of Mycobacterium Ulcerans Osteomyelitis with Minor Surgical Debridement and Prolonged Rifampicin and Ciprofloxacin Therapy: A Case Report
        Dilation of Renal Artery Stenosis after Administration of Losartan

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Metformin Improves Metabolic Control and Other Physiologic Variables in Type 2 Diabetes

        A DGReview of :"Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy"
        Clinical Therapeutics

        02/25/2004
        By Mary Beth Nierengarten


        Treatment of type 2 diabetes with metformin effectively lowers blood glucose levels, benefits lipid profiles, improves vascular and haemodynamic indices, and is generally well tolerated, report researchers.

        Stephen M. Setter, PharmD, CDE, DVM, Washington State University, Spokane, United States, and colleagues conducted a comprehensive literature review of the pharmacology, pharmacokinetics, adverse effects, drug-interaction potential, dosing guidelines, clinical efficacy and safety, and pharmacoeconomics of the biguanide agent metformin hydrochloride.

        Available in Europe since the 1950s, metformin was only approved for use in the US in 1994; in October 2000, it was approved in an extended-release (XR) formulation that combined metformin with glyburide, rosiglitazone, or glipizide.

        As the only currently available oral antidiabetic and hypoglycaemic agent that acts primarily by inhibiting hepatic glucose release, metformin has been shown to effectively lower blood glucose levels and improve lipid profiles. When used as monotherapy or combined with other agents, metformin is associated with a 1% to 2% reduction in glycosylated haemoglobin (HbA1c).

        Clinical data based on a number of well-designed randomised trials confirm the metabolic control and improvements in lipids and vascular parameters achieved by metformin alone or in combination. Emphasised in this review is the efficacy of dual therapy, given in the form of separate agents (metformin plus a thiazolidinedione, a "glitinide," or an alpha-glucosidase inhibitor) or as a combination agent (metformin plus a sulfonylurea).

        Overall, metformin is well tolerated with mostly transient gastrointestinal adverse effects - the most common event occurring in up to 50% of the patients. Lactic acidosis is the most serious side effect; though rare (about 8 cases in 100,000 person-years), it causes death in 50% of the patients who develop it.

        Based on these data, the authors conclude that "with the recent introduction of combination products containing metformin and rosiglitazone or a sulfonylurea, health care providers have an expanded array of therapies for the management of type 2 diabetes."

        Clin Ther 2003 Dec;25:12:2991-3026. "Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send